ACQ2 by Acquired

The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

Mar 6, 2024

01:00:05

Snipd AI

Dive into the fascinating world of Ozempic's scientific journey with Novo Nordisk's chief scientific advisor. Learn about the science behind weight loss on Ozempic, the 90s belief in a groundbreaking drug, and weight loss as a primary goal from the start. Explore the challenges and innovations in developing pharmaceutical technologies and the mechanisms of GOP one agents for diabetes and weight loss.

AI Summary

Highlights

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

GLP-1 agonists like Semaglutide work by increasing insulin levels and lowering glucagon levels for blood glucose control.

Innovative chemical engineering efforts led to the development of Semaglutide with an extended half-life and increased weight loss outcomes.

The success of developing GLP-1 agonists for weight loss and diabetes treatment was driven by perseverance, belief in data, and challenging industry norms.

Deep dives

The Science behind GLP1 Agonists for Weight Loss and Diabetes Treatment

GLP1 agonists like Lira Glutide and Semaglutide work by increasing insulin levels and lowering glucagon levels, thereby reducing blood glucose. They also slow down food absorption in the intestine, helping to stabilize blood glucose levels after eating. Additionally, these medications help individuals consume fewer calories, leading to weight loss. The availability of Semaglutide once weekly injection provided a longer-lasting effect with doubled weight loss outcomes by reducing energy intake compared to Lira Glutide.

Exploring the Mechanisms of Lerakotide and Semagotide in Obesity Treatment

02:51

Slow Progress with Consistent Positive Data

01:01

Exploring the Science of Weight Loss Medication Development

03:26

Dual Mechanisms for Treating Diabetes and Obesity

01:27

Introduction

4min

Journey from Enzymes to GLP1 Research

21min

Navigating the Collaboration-Competition Conundrum in Research Communities

5min

Platform Technology in Pharmaceuticals and Introduction of Quarter Pro Sponsor

2min

Understanding the Mechanisms of GOP One Agents for Diabetes Management and Weight Loss

3min

Understanding GLP-1 Medications for Weight Loss and Diabetes Control

14min

Exploration of Molecule Testing Processes and Evolution in Pharmaceutical Research

2min

Exploring AI Applications and Data Analysis in Science and Research

9min

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:

The science behind what is happening in the body that causes weight loss while on Ozempic
What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!

Sponsors:

Vanta

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

ACQ2 by Acquired

The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

The Science behind GLP1 Agonists for Weight Loss and Diabetes Treatment

Innovative Chemical Engineering for Long-Lasting GLP1 Agonists

Navigating Challenges and Achieving Success in Pharmaceutical Innovation

Evolving Pharmaceutical Research with AI and Collaborative Efforts

Personal Resilience and Professional Dedication in Transformative Medical Discoveries

Exploring the Mechanisms of Lerakotide and Semagotide in Obesity Treatment

Slow Progress with Consistent Positive Data

Exploring the Science of Weight Loss Medication Development

Dual Mechanisms for Treating Diabetes and Obesity

Get the Snipd
podcast app

AI-powered
podcast player

Discover
highlights

Save any
moment

Share
& Export

AI-powered
podcast player

Discover
highlights

ACQ2 by Acquired

The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

The Science behind GLP1 Agonists for Weight Loss and Diabetes Treatment

Innovative Chemical Engineering for Long-Lasting GLP1 Agonists

Navigating Challenges and Achieving Success in Pharmaceutical Innovation

Evolving Pharmaceutical Research with AI and Collaborative Efforts

Personal Resilience and Professional Dedication in Transformative Medical Discoveries

Exploring the Mechanisms of Lerakotide and Semagotide in Obesity Treatment

Slow Progress with Consistent Positive Data

Exploring the Science of Weight Loss Medication Development

Dual Mechanisms for Treating Diabetes and Obesity

Get the Snipdpodcast app

AI-poweredpodcast player

Discoverhighlights

Save anymoment

Share& Export

AI-poweredpodcast player

Discoverhighlights

Get the Snipd
podcast app

AI-powered
podcast player

Discover
highlights

Save any
moment

Share
& Export

AI-powered
podcast player

Discover
highlights